You searched for "nAMD"
EDOF intraocular lens in eyes with preexisting retinal disease
Extended depth of focus (EDOF) intraocular lens (IOL) offers improved near and intermediate vision, aiming to reduce spectacle dependence in cataract patients. This study aims to evaluate the performance of EDOF lenses following cataract surgery in patients with retinal pathology....MacuMira and Keeler announce strategic partnership to expand dry AMD therapy
Keeler, a global leader in ophthalmic innovation with more than a century of heritage, and MacuMira Medical Devices Inc, a pioneering Canadian company, has announced a strategic partnership. Under the agreement, Keeler will manufacture the MacuMira device and lead its...Over 8700 Scots will lose their sight this year
New data from sight loss charity RNIB reveals that 8730 people in Scotland will begin living with sight loss in the next 12 months alone, and that the total number of people affected is set to grow by nearly 21%...‘Agenda-setting’ BCLA Clinical Conference to shape the future of contact lens practice around the world
The global eye care professional network’s “unquenchable thirst for learning” ensured the success of the first in-person BCLA Clinical Conference & Exhibition in four years.How a calcified Soemmerring ring was removed from the vitreous cavity when the cutter and forceps failed to do so
Know’st thou the land where lemon-trees do bloom,And oranges like gold in leafy gloom; A gentle wind from deep blue heaven blows, The myrtle thick, and high the laurel grows? ‘Tis there! ‘tis there, O my beloved one, I with...The blue-light hazard – is it true?
Simerdip Kaur takes a look at the latest ophthalmology-related news stories and asks which are based on facts and which are ‘fake news’. Headline: The blue-light hazard – is it true? Blue light is part of the visible optical spectrum...
Ophthalmology (third edition)
If you are an ophthalmologist who enjoys books with coloured pictures, you’re no lone wolf. The third edition of Lang’s Ophthalmology will definitely pique your primal ophthalmologist instincts. You will be drawn to its soft-bound yet sturdy looking exterior. Flicking...
Data update for leading causes of CVI in England and Wales
In this article the authors present an epidemiological update, based on certifiable visual impairment (CVI) registration for figures for sight impairment (SI) in England and Wales from the last report of 2007-2008 to the current data for April 2012 to...
Systemic pharmacology of intravitreal anti-VEGF
This study aimed to evaluate and compare serum drug concentrations and plasma free-VEGF concentrations in patients with AMD, DME, or RVO receiving intravitreal injections of aflibercept, bevacizumab or ranibizumab. This prospective study enrolled patients from several offices of a single...
Macular atrophy with aflibercept
The authors of this paper set out to investigate the prevalence of macular atrophy in treatment-naive patients with neovascular AMD undergoing aflibercept monotherapy (three monthly loading injections followed by subsequent treatment every two months). Case notes over a three year...
The effects of anti-VEGF therapy for NvAMD on retinal vasculature
This retrospective consecutive case series examined 54 eyes of 54 treatment-naïve neovascular age-related macular degeneration (N-AMD) patients. Thirty-three eyes received intravitreal aflibercept injections, and 21 eyes received intravitreal ranibizumab injections with unaffected fellow eyes (54 eyes) as controls. All image...
